icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
fNwhVnkKtKQdQWL9
Listen
